Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
August 12, 2021
This first episode of the new Africa-centered podcast series Lagos to Mombasa examines how African governments can shape their responses to the pandemic and prepare for the future. Patrick Tippoo of Biovac and the African Vaccine Manufacturing Initiative and Prashant Yadav from CGD join Gyude M...
Jul
13
2021
2:00—3:15 PM Washington DC Time
July 07, 2021
Ensuring access, affordability, and equity to essential medicines and other health products is critical to strong health systems. COVID-19 has shown how quickly failing to safeguard these principles reverses progress towards universal access to health and universal health coverage. Coordination and ...
Blog Post
June 04, 2021
Since March of 2020, COVID-19 changed most aspects of life as we knew it, from our personal day-to-day activities to the systems, processes, and structures that keep the global economy interconnected and moving. This included pharmaceutical production and distribution, where anecdotal evidence ...
Blog Post
May 25, 2021
A lot of recent discussions focus on how to expand COVID-19 vaccine manufacturing capacity in low- and middle-income countries (LMICs). The conversations highlight the importance of technology transfer and the capability of the tech transfer receiving sites (the facilities in these countries that wo...
Blog Post
March 26, 2021
Safe and efficacious vaccines are our best tools for defeating COVID-19. An unprecedented research and development effort has led to 12 vaccines with full or limited use emergency authorizations globally, but vaccinating everyone in the world as quickly as possible will require additional production...
CGD NOTES
March 26, 2021
Safe and efficacious vaccines are our best tools for defeating COVID-19, and an unprecedented research and development effort has led to 12 vaccines being approved for full, emergency, or limited use, globally. But to vaccinate the global population as quickly as possible requires additional product...
Oct
2
2020
9:00—10:30 AM EDT
August 14, 2020
Much of the discussion around society’s ability to return to “normality” after the COVID-19 pandemic has centered on the development of a vaccine. This has led to unprecedented collaboration and investment. Vaccine candidate development for COVID-19 is progressing faster than for any other pathogen ...